Patents by Inventor Elodie Pliquet

Elodie Pliquet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant measles vaccine expressing hTERT
    Patent number: 11351246
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: June 7, 2022
    Assignees: INVECTYS SAS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Langlade Demoyen, Frédéric Tangy, Elodie Pliquet
  • RECOMBINANT MEASLES VACCINE EXPRESSING HTERT
    Publication number: 20210077613
    Abstract: The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.
    Type: Application
    Filed: May 7, 2018
    Publication date: March 18, 2021
    Applicants: INVECTYS, INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre LANGLADE DEMOYEN, Frédéric TANGY, Elodie PLIQUET
  • Telomerase encoding DNA vaccine
    Patent number: 10183065
    Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: January 22, 2019
    Assignee: INVECTYS
    Inventors: Pierre Langlade Demoyen, Simon Wain-Hobson, Thierry Huet, Christelle Liard, Elodie Pliquet
  • TELOMERASE ENCODING DNA VACCINE
    Publication number: 20190000946
    Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.
    Type: Application
    Filed: August 24, 2018
    Publication date: January 3, 2019
    Applicant: INVECTYS
    Inventors: Pierre Langlade Demoyen, Simon Wain-Hobson, Thierry Huet, Christelle Liard, Elodie Pliquet
  • TELOMERASE ENCODING DNA VACCINE
    Publication number: 20160263204
    Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.
    Type: Application
    Filed: October 28, 2014
    Publication date: September 15, 2016
    Applicant: INVECTYS
    Inventors: Pierre Langlade Demoyen, Simon Wain-Hobson, Thierry Huet, Christelle Liard, Elodie Pliquet